Guggenheim Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $45.00

Intellia Therapeutics (NASDAQ:NTLA) had its price target cut by Guggenheim from $55.00 to $45.00 in a research note released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also recently weighed in on NTLA. Wells Fargo & Company lowered their target price on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Citigroup lowered their target price on Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating on the stock in a research note on Friday, May 9th. Barclays lowered their target price on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Oppenheimer lowered their target price on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. Finally, HC Wainwright assumed coverage on Intellia Therapeutics in a research note on Wednesday, March 5th. They set a “buy” rating and a $30.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.90.

Intellia Therapeutics Stock Down 5.3%

Shares of NASDAQ NTLA opened at $7.88 on Monday. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The firm’s 50-day simple moving average is $8.08 and its 200 day simple moving average is $10.90. The stock has a market cap of $816.23 million, a P/E ratio of -1.45 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.16. The company had revenue of $16.63 million during the quarter, compared to analysts’ expectations of $11.39 million. The company’s revenue for the quarter was down 42.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.12) EPS. On average, sell-side analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Intellia Therapeutics by 125.2% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company’s stock worth $1,411,000 after buying an additional 67,276 shares during the last quarter. Avanza Fonder AB acquired a new position in shares of Intellia Therapeutics in the fourth quarter valued at $421,000. Barclays PLC raised its stake in shares of Intellia Therapeutics by 17.7% in the third quarter. Barclays PLC now owns 292,795 shares of the company’s stock valued at $6,017,000 after purchasing an additional 44,022 shares in the last quarter. ARK Investment Management LLC raised its stake in shares of Intellia Therapeutics by 2.3% in the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock valued at $146,174,000 after purchasing an additional 280,946 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of Intellia Therapeutics by 85.7% in the fourth quarter. SG Americas Securities LLC now owns 44,838 shares of the company’s stock valued at $523,000 after purchasing an additional 20,694 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.